Atherosclerosis, chronic inflammatory process progressing from fatty lesions to fibrous and unstable plaques, is the major underlying factor in most cases of coronary heart disease. Clinical disease as a result of atherosclerotic disease remains as the leading determinant for the extensive mortality and morbidity. and exorbitant health care costs in our society. The """"""""LDL oxidation"""""""" hypothesis has gained general acceptance as a leading player in atherogenesis and it is recognized that oxidized LDL exhibits many pro-atherogenic properties. properties. The factors that initiate LDL, oxidating in vivo are poorly understood. However, circumstantial evidence has placed the 12/15-lipoxygenase in the context of atherosclerosis. Thus, in the first specific aim, the role of 12/15- lipoxygenase in mouse models of atherosclerosis (apoB editing catalytic polypeptide-1 (apobec-1)/LDL-receptor deficient and apoE deficient) will be assessed by quantitating lesion development throughout the aorta by the """"""""en face"""""""" method using appropriately crossbred 12/15-lipoxygenase deficient mice. The combined effects of the anti-oxidant vitamin E with 12/15-lipooxygenase deficiency will also be examined. Total cholesterol, triglycerides, lipoprotein profiles and oxidative stress markers known as isoprostanes will be measured and correlated with lesion development. If specific 12/15-lipoxygenase inhibitors are ultimately to be used in atherosclerotic disease management they will need to be effective in limiting, or causing regression of, pre-existing lesion. By using an inducible 12/15-lipoxygenase gene disruption strategy in mice with atherosclerosis at various stages this important matter will be addressed.
In specific aim 2, the subset of macrophages expressing 12/15- lipoxygenase will be characterized and purified. The effects of lipid loading and factors regulating 12/15-lipoxygenase gene expression will be determined.
In specific aim 3, the novel 12(R)-lipoxygenase will be characterized and its relevance to atherosclerosis and LDL oxidation discerned.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL053558-08
Application #
6351483
Study Section
Pathology A Study Section (PTHA)
Program Officer
Goldman, Stephen
Project Start
2000-02-01
Project End
2004-01-31
Budget Start
2001-02-01
Budget End
2002-01-31
Support Year
8
Fiscal Year
2001
Total Cost
$313,321
Indirect Cost
Name
University of Pennsylvania
Department
Pharmacology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
FitzGerald, Garret A (2008) Translational therapeutics at the platelet vascular interface. Introduction. Arterioscler Thromb Vasc Biol 28:s3-4
FitzGerald, Garret A (2008) Translational therapeutics at the platelet vascular interface. Summary. Arterioscler Thromb Vasc Biol 28:s51-2
Cao, Richard Yang; Adams, Michael A; Habenicht, Andreas J et al. (2007) Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostaglandins Other Lipid Mediat 84:34-42
Funk, Colin D; Cao, Richard Yang; Zhao, Lei et al. (2006) Is there a role for the macrophage 5-lipoxygenase pathway in aortic aneurysm development in apolipoprotein E-deficient mice? Ann N Y Acad Sci 1085:151-60
Zhao, Lei; Pratico, Domenico; Rader, Daniel J et al. (2005) 12/15-Lipoxygenase gene disruption and vitamin E administration diminish atherosclerosis and oxidative stress in apolipoprotein E deficient mice through a final common pathway. Prostaglandins Other Lipid Mediat 78:185-93
Chinnici, Cinzia M; Yao, Yuemang; Ding, Tao et al. (2005) Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am J Pathol 167:1371-7
Anning, Peter B; Coles, Barbara; Bermudez-Fajardo, Alexandra et al. (2005) Elevated endothelial nitric oxide bioactivity and resistance to angiotensin-dependent hypertension in 12/15-lipoxygenase knockout mice. Am J Pathol 166:653-62
Tietge, Uwe J F; Pratico, Domenico; Ding, Tao et al. (2005) Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res 46:1604-14
Wang, Dairong; Wong, Dairong; Wang, Miao et al. (2005) Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 5:204-10
Zhao, Lei; Moos, Michael P W; Grabner, Rolf et al. (2004) The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10:966-73

Showing the most recent 10 out of 38 publications